The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseThomas O. Bergmeijer, Paul A. Gurbel, Stefan James et al.|Thrombosis and Haemostasis|2014Cited by 32
TCT-49 A Comparison of 5 mg Prasugrel With 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment ReactivityJoseph A. Jakubowski, Dominick J. Angiolillo, David Erlinge et al.|Journal of the American College of Cardiology|2012Cited by 0